Drug treatment of idiopathic pulmonary fibrosis systematic review and network meta-analysis

Chest

Volumn 149, Issue 3, 2016, Pages 756-766

  Canestaro, William J ^a   Forrester, Sara H ^b   Raghu, Ganesh ^c   Ho, Lawrence ^c   Devine, Beth E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Epidemiology (pulmonary); Evidence based medicine; Idiopathic pulmonary fibrosis; Meta analysis

Indexed keywords

ACETYLCYSTEINE; AMBRISENTAN; AZATHIOPRINE; BOSENTAN; COLCHICINE; ETANERCEPT; GAMMA1B INTERFERON; IMATINIB; MACITENTAN; NINTEDANIB; PIRFENIDONE; WARFARIN; ANTICOAGULANT AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ENZYME INHIBITOR; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INDOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; RECOMBINANT PROTEIN; SCAVENGER; SULFONAMIDE;

ARTICLE; CAUSE OF DEATH; DRUG EFFECT; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; BAYES THEOREM; IDIOPATHIC PULMONARY FIBROSIS; VITAL CAPACITY;

ACETYLCYSTEINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; AZATHIOPRINE; BAYES THEOREM; ENDOTHELIN RECEPTOR ANTAGONISTS; ENZYME INHIBITORS; ETANERCEPT; FREE RADICAL SCAVENGERS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMATINIB MESYLATE; IMMUNOSUPPRESSIVE AGENTS; INDOLES; INTERFERON-GAMMA; PHENYLPROPIONATES; PYRIDAZINES; PYRIDONES; PYRIMIDINES; RECOMBINANT PROTEINS; SULFONAMIDES; VITAL CAPACITY; WARFARIN;

EID: 84960465430     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2015.11.013     Document Type: Article

References (29)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
2. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810-816.
3. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3-e19.
4. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7): 566-572.
5. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-691.
6. Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999;159(4 pt 1): 1061-1069.
7. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040-1047.
8. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821-829.
9. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779): 1760-1769.
10. King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.
11. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-1087.
12. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.
13. Loveman E, Copley VR, Scott DA, et al. Comparing new treatments for idiopathic pulmonary fibrosis - A network meta-analysis [published online ahead of print April 18, 2015]. BMC Pulm Med. http://dx.doi.org/10.1186/s12890-015-0034-y.
14. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. New York, NY: Wiley; 2011.
15. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777-784.
16. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(1): e1-e34.
17. Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010:CD003134.
18. Turner RM, Davey J, Clarke MJ, Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012;41(3):818-827.
19. Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graphic Statistics. 1998;7:434-455.
20. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 2013;33(5):641-656.
21. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163-171.
22. du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183(9): 1231-1237.
23. Brown S, Hutton B, Clifford T, et al. A Microsoft-Excel-based tool for running and critically appraising network meta-analyses-an overview and application of NetMetaXL [published online ahead of print September 29 2014]. Syst Rev. http://dx.doi.org/10.1186/2046-4053-3-110.
24. Agapova M, Devine EB, Nguyen H, et al. Using indirect comparisons to compare interventions within a Cochrane review: a tool for comparative effectiveness research. J Comp Eff Res. 2014;3(4): 345-357.
25. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis: a randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med. 1998;158:220-225.
26. Zisman DA, Schwarz M, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620-628.
27. Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264-1269.
28. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med. 2012;31(25):2973-2984.
29. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med. 2015;191(3): 252-254.